

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
01 FEB 14 PM 2:22

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pharmaceutical Research & Manufacturers of America	
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address: 1100 15th Street, N.W., Suite 900 City: Washington State/Zip (or Country): DC 20005 USA	
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____	
4. Contact Name Matthew B. Van Hook	5. Senate ID # 31350-12
7. Client Name <input checked="" type="checkbox"/> Self	6. House ID # 30654000

8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$3,500,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
--	--

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 1 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R. 4461, Appropriations for the Department of Agriculture and Related Agencies, FDA Appropriations
S. 2536, Appropriations for the Department of Agriculture and Related Agencies, FDA Appropriations

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Christy, James		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Holmer, Alan F.		No
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	No
Lynch, Ann-Marie	Staff Dir., House Ways & Means Health Subctee	No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 2 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew R.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

- H.R. 1598, Patent Fairness Act of 1999, Limited to support for the concept of patent term restoration
- H.R. 4461, Appropriations for the Department of Agriculture and Related Agencies, including FDA, Oppose amendments to extend patent restoration under the Hatch-Waxman Act to products that do not require FDA approval prior to marketing.
- H.R. 5231, Generic Drug Amendments Act of 2000, Hatch-Waxman Act
- H.R. 5235, Prescription Drug Competition Act of 2000, Hatch-Waxman Act
- H.R. 5247, Greater Access to Affordable Pharmaceuticals Act, Hatch-Waxman Act
- H.R. 5313, Drug Competition Act of 2000, Hatch-Waxman Act
- H.R. 626, Health Care Research and Development and Taxpayer Protection Act, Oppose imposition of a counterproductive "reasonable pricing clause" on NIH patent licenses
- S. 3051, Greater Access to Affordable Pharmaceuticals Act, Hatch-Waxman Act

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Patent and Trademark Office
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Bello, Judith		No
Christy, James		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Holmer, Alan F.		No
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 4 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 1172, Drug Patent Term Restoration Review Procedure Act of 1999, Limited to support for the concept of patent term restoration, except to also urge deletion of provisions different from H.R. 1598, which are unnecessary to the goals of H.R. 1598
16	Lobbying Issues	S. 2536, Appropriations for the Department of Agriculture and Related Agencies, including FDA. Oppose amendments to extend patent restoration under the Hatch-Waxman Act to products that do not require FDA approval prior to marketing.
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R. 1885, International Prescription Drug Parity Act,
H.R. 2470, Medical Information Protection & Research Enhancement Act of 1999,
H.R. 2782, The Seniors Prescription Insurance Coverage Act of 1999,
H.R. 3240, The Drug Import Fairness Act,
H.R. 4461, Agriculture Appropriations, Section 745, "Medicine Equity and Drug Safety Act of 2000," and Section 746, "Prescription Drug Import Fairness Act of 2000"
H.R. 4680, Medicare Rx 2000,
H.R. 664, Prescription Drug Fairness Act of 1999,
S. 1191, International Prescription Drug Parity Act,
S. 1480, The Seniors Prescription Insurance Coverage Equity Act of 1999,
S. 2464, Prescription Drug Fairness Act,

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Bello, Judith		No
Christy, James		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Guarducci, Mara	Legislative Assistant, Rep. Jim Greenwood	No
Holmer, Alan F.		No
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 6 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 2466, (to require the U.S. Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs).
16	Lobbying Issues	S. 2520, Medicine Equity and Drug Safety Act of 2000,
16	Lobbying Issues	S. 2541, Medicare Expansion for Needed Drugs (MEND) Act of 2000,
16	Lobbying Issues	S. 2807, Medicare Prescription Drug & Modernization Act,
16	Lobbying Issues	S. 2836, Medicare Rx Drug Discount and Security Act of 2000,
16	Lobbying Issues	S. 578, Health Information Protection Act.
16	Lobbying Issues	S. 731, Prescription Drug Fairness Act of 1999,
16	Lobbying Issues	S. 881, Medical Information Protection Act of 1999,
16	Lobbying Issues	Executive Branch: FDA implementation of P.L. 105-115, the FDA Modernization Act of 1997

18a	Lobbyist Name	Lucas, William
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Lynch, Ann-Marie
18b	Covered Official Position	Staff Dir., House Ways & Means Health Subcttee
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R. 1495, Access Medicare Prescription Drug Coverage Act of 1999,
H.R. 2012, Medicare Prescription Drug Act of 1999,
H.R. 2375, Senior Prescription Drug Assistance Expansion Demonstration Act of 1999,
H.R. 2927, Affordable Prescription Drug Act.
H.R. 4680, Medicare Rx 2000,
H.R. 664, Prescription Drug Fairness for Seniors Act of 1999,
H.R. 886, Medicare Prescription Drug Coverage Act of 1999,
S. 1204, Healthy Seniors Promotion Act of 1999,
S. 1480, Seniors Prescription Insurance Coverage Equity Act of 1999,
S. 1895, Medicare Preservation and Improvement Act of 1999,
S. 2541, Medicare Expansion for Needed Drugs (MEND) Act of 2000,

17. House(s) of Congress and Federal agencies contacted Check if None
Health Care Financing Administration, Dept. of Health and Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bello, Judith		No
Christy, James		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Guarducci, Mara	Legislative Assistant, Rep. Jim Greenwood	No
Holmer, Alan F.		No
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	No
Lucas, William		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 8 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 2807, Medicare Prescription Drug & Modernization Act,
16	Lobbying Issues	S. 2836, Medicare Rx Drug Discount and Security Act of 2000.
16	Lobbying Issues	Executive Branch: Medicare reimbursement issues.
18a	Lobbyist Name	Lynch, Ann-Marie
18b	Covered Official Position	Staff Dir., House Ways & Means Health Subctee
18c	New Lobbyist	No
18a	Lobbyist Name	Robinson, Josephine
18b	Covered Official Position	
18c	New Lobbyist	Yes
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Walters, William
18b	Covered Official Position	Counsel, House Committee on Ways and Means
18c	New Lobbyist	Yes

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R. 2488, Financial Freedom Act of 1999, re health care deductions
H.R. 3665 and S. 2465, Prescription Price Equity Act,
H.R. 4686, Fair Balance Prescription Drug Advertising Act,
H.R. 4986, FSC Repeal and Extraterritorial Income Exclusion Act of 2000, Development of FSC replacement
S. 1429, Taxpayer Refund Act of 1999,
Department of the Treasury development of a Foreign Sales Corporation replacement proposal in response to a decision of the World Trade Organization.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Christy, James		No
Currie, Rodger	Majority Counsel, House Commerce Committee	No
Guarducci, Mara	Legislative Assistant, Rep. Jim Greenwood	No
Holmer, Alan F.		No
Jones, Rebecca	Prof. Staff Member, Senate Special Ctee on Aging	No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 10 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R. 434, Africa Growth & Opportunity Act,

Congressional Matters:

FY 2001 Appropriations -- Foreign Operations, Export Financing and Related Programs

Renewing Trade Negotiation Authority; Strengthening Protection of Intellectual Property

FY 2001 Appropriations -- Commerce, Justice, State Department appropriations bill (re protecting intellectual property rights).

Executive Branch:

Strengthening protection of Intellectual property -- accession of China to the WTO; South Africa

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce

House of Representatives

Office of the United States Trade Representative

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bello, Judith		No
Christy, James		No
Herzfeld, Shannon S.S.		No
Holmer, Alan F.		No
Lucas, William		No
Rubin, Peter	Legislative Director for Rep. Jim McDermott	No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 11 of 12

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Cole, Steven
Mohler, Dave T.

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature  Date 2/9/01

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 12 of 12